Constellation Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CNST)

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals Inc (NASDAQ:CNST) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.80). View Constellation Pharmaceuticals' Earnings History.

Constellation Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Constellation Pharmaceuticals.

4 analysts have issued 12-month price targets for Constellation Pharmaceuticals' stock. Their forecasts range from $17.00 to $20.00. On average, they anticipate Constellation Pharmaceuticals' share price to reach $18.25 in the next twelve months. This suggests a possible upside of 150.7% from the stock's current price. View Analyst Price Targets for Constellation Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Constellation Pharmaceuticals.

Media headlines about CNST stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Constellation Pharmaceuticals earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Constellation Pharmaceuticals.

Some companies that are related to Constellation Pharmaceuticals include ZEALAND PHARMA/S (ZEAL), Endo International (ENDP), Kura Oncology (KURA), Urogen Pharma (URGN), ZIOPHARM Oncology (ZIOP), Stoke Therapeutics (STOK), Vanda Pharmaceuticals (VNDA), Capstone Therapeutics (CAPS), Karyopharm Therapeutics (KPTI), Catalyst Pharmaceuticals (CPRX), Advanz Pharma (CXRXF), Rocket Pharmaceuticals (RCKT), OrganiGram (OGI), MacroGenics (MGNX) and Vectura Group (VEGPF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Anavex Life Sciences (AVXL), Corbus Pharmaceuticals (CRBP), Momo (MOMO), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), AVEO Pharmaceuticals (AVEO), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR) and Novus Therapeutics (NVUS).

(CNST) raised $80 million in an IPO on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.18%), Vanguard Group Inc. (2.05%), Northern Trust Corp (0.57%), P.A.W. Capital Corp (0.46%), Alps Advisors Inc. (0.21%) and Bank of New York Mellon Corp (0.14%). Company insiders that own Constellation Pharmaceuticals stock include Alexandria Venture Investments, Anthony B Evnin and James E Flynn. View Institutional Ownership Trends for Constellation Pharmaceuticals.

CNST stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. View Insider Buying and Selling for Constellation Pharmaceuticals.

CNST stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., P.A.W. Capital Corp, BlackRock Inc., Alps Advisors Inc., Jacobs Levy Equity Management Inc., Northern Trust Corp, Acadian Asset Management LLC and Wells Fargo & Company MN. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin and James E Flynn. View Insider Buying and Selling for Constellation Pharmaceuticals.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $7.28.

Constellation Pharmaceuticals has a market capitalization of $187.97 million. The company earns $-59,920,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.View Additional Information About Constellation Pharmaceuticals.

The official website for Constellation Pharmaceuticals is http://www.constellationpharma.com/.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]